Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes.

Methods

Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS.

Results

Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10−6) and stage IV (P = 10−5) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05).

Conclusions

Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Bea S, Tort F, Pinyol M et al (2001) BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61:2409–2412

    PubMed  CAS  Google Scholar 

  • Breuer RH, Snijders PJ, Smit EF et al (2004) Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6:736–743

    Article  PubMed  CAS  Google Scholar 

  • Breuer RH, Snijders PJ, Sutedja GT et al (2005) Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 48:299–306

    Article  PubMed  CAS  Google Scholar 

  • Broers JL, Viallet J, Jensen SM et al (1993) Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am J Respir Cell Mol Biol 9:33–43

    PubMed  CAS  Google Scholar 

  • Bruggeman SW, Valk-Lingbeek ME, van der Stoop PP et al (2005) Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 19:1438–1443

    Article  PubMed  CAS  Google Scholar 

  • Denlinger CE, Rundall BK, Jones DR (2004) Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-kappaB. Semin Thorac Cardiovasc Surg 16:28–39

    Article  PubMed  Google Scholar 

  • Dimri GP, Martinez JL, Jacobs JJ et al (2002) The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 62:4736–4745

    PubMed  CAS  Google Scholar 

  • Doyle LA (1993) Mechanisms of drug resistance in human lung cancer cells. Semin Oncol 20:326–337

    PubMed  CAS  Google Scholar 

  • Dubey S, Schiller JH (2005) Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. Oncologist 10:282–291

    Article  PubMed  CAS  Google Scholar 

  • Dukers DF, van Galen JC, Giroth C et al (2004) Unique polycomb gene expression pattern in Hodgkin’s lymphoma and Hodgkin’s lymphoma-derived cell lines. Am J Pathol 164:873–881

    PubMed  CAS  Google Scholar 

  • Dutton A, Woodman C, Chukwuma M et al (2007) Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood 109:2597–2603

    Article  PubMed  CAS  Google Scholar 

  • Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115:1503–1521

    Article  PubMed  CAS  Google Scholar 

  • Guney I, Wu S, Sedivy JM (2006) Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16 (INK4a). Proc Natl Acad Sci USA 103:3645–3650

    Article  PubMed  CAS  Google Scholar 

  • Iwama A, Oguro H, Negishi M et al (2004) Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 21:843–851

    Article  PubMed  CAS  Google Scholar 

  • Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29

    Article  PubMed  Google Scholar 

  • Kim JH, Yoon SY, Jeong SH et al (2003) Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 13:383–388

    Article  Google Scholar 

  • Kim JH, Yoon SY, Kim CN et al (2004) The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203:217–224

    Article  PubMed  CAS  Google Scholar 

  • Leung C, Lingbeek M, Shakhova O et al (2004) Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428:337–341

    Article  PubMed  CAS  Google Scholar 

  • Levine SS, King IF, Kingston RE (2005) Division of labor in polycomb group repression. Trends Biochem Sci 29:478–485

    Article  CAS  Google Scholar 

  • Liu JH, Song LB, Zhang X et al (2008) Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol (in press)

  • Lowe SW, Sherr CJ (2003) Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 13:77–83

    Article  PubMed  CAS  Google Scholar 

  • Lund AH, van Lohuizen M (2004) Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 16:239–246

    Article  PubMed  CAS  Google Scholar 

  • Mihara K, Chowdhury M, Nakaju N et al (2006) Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 107:305–308

    Article  PubMed  CAS  Google Scholar 

  • Molofsky AV, He S, Bydon M et al (2005) Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 19:1432–1437

    Article  PubMed  CAS  Google Scholar 

  • Nowak K, Kerl K, Fehr D et al (2006) BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 34:1745–1754

    Article  PubMed  CAS  Google Scholar 

  • Park IK, Qian D, Kiel M et al (2003) Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423:302–305

    Article  PubMed  CAS  Google Scholar 

  • Raaphorst FM (2005) Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors. Hum Mol Genet 14:R93–R100

    Article  PubMed  CAS  Google Scholar 

  • Raaphorst FM, van Kemenade FJ, Blokzijl T et al (2000) Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin’s disease. Am J Pathol 157:709–715

    PubMed  CAS  Google Scholar 

  • Sandler AB, Johnson DH, Herbst RS (2004) Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10:4258s–4262s

    Article  PubMed  CAS  Google Scholar 

  • Satijn DP, Otte AP (1999) Polycomb group protein complexes: do different complexes regulate distinct target genes? Biochem Biophys Acta 1447:1–16

    PubMed  CAS  Google Scholar 

  • Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Article  PubMed  CAS  Google Scholar 

  • Sewalt RG, van der Vlag J, Gunster MJ et al (1998) Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol 18:3586–3595

    PubMed  CAS  Google Scholar 

  • Silva J, García V, García JM et al (2008) Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res (in press)

  • Silvestri GA, Rivera MP (2005) Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 128:3975–3984

    Article  PubMed  CAS  Google Scholar 

  • Shao Z, Raible F, Mollaaghababa R et al (1999) Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell 98:37–46

    Article  PubMed  CAS  Google Scholar 

  • Sherr CJ (2001) The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 10:731–737

    Article  CAS  Google Scholar 

  • Song LB, Zeng MS, Liao WT et al (2006) Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 15:6225–6232

    Article  Google Scholar 

  • van Kemenade FJ, Raaphorst FM, Blokzijl T et al (2001) Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97:3896–3901

    Article  PubMed  Google Scholar 

  • Vonlanthen S, Heighway J, Altermatt HJ et al (2001) The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84:1372–1376

    Article  PubMed  CAS  Google Scholar 

  • Wang H, Pan K, Zhang HK et al (2008) Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol (in press)

  • Yu Q, Su B, Liu D et al (2007) Antisense RNA-mediated suppression of Bmi-1 gene expression inhibits the proliferation of lung cancer cell line A549. Oligonucleotides 17:327–335

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported in parts from the Grant Agency for Advancement of Czech Universities (FRVS 1722/2006), Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA MZ ČRNR/8425-3/2005 and IGA MZ CR NR 8370-3) and Ministry of School and Education of the Czech Republic (MSM6198959216).

Author information

Authors and Affiliations

  1. Laboratory of Molecular Pathology, Department of Pathology, Palacky University, Olomouc, Czech Republic

    Katerina Vrzalikova, Joseph Skarda, Jiri Ehrmann, Petra Knizetova & Zdenek Kolar

  2. Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Birmingham, UK

    Paul G. Murray

  3. Department of Pathology, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    Eduard Fridman & Jury Kopolovic

  4. Laboratory of Experimental Medicine, Department of Pediatrics, Palacky University, Olomouc, Czech Republic

    Marian Hajduch

  5. 1st Department of Surgery, Medical Faculty, Palacky University, Olomouc, Czech Republic

    Jiri Klein

  6. Department of Tuberculosis and Respiratory Diseases, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

    Vitezslav Kolek

  7. Department of Pediatrics, Medical Faculty, Palacky University, Olomouc, Czech Republic

    Lenka Radova

Authors
  1. Katerina Vrzalikova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph Skarda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiri Ehrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul G. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eduard Fridman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jury Kopolovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Petra Knizetova
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marian Hajduch
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jiri Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Vitezslav Kolek
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lenka Radova
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Zdenek Kolar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katerina Vrzalikova.

Additional information

Katerina Vrzalikova and Joseph Skarda have equal rights.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vrzalikova, K., Skarda, J., Ehrmann, J. et al. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol 134, 1037–1042 (2008). https://doi.org/10.1007/s00432-008-0361-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-008-0361-y

Keywords

Search

Navigation